Atopic Dermatitis

The panelist discusses how to effectively communicate with patients about nonsteroidal topical treatment options for atopic dermatitis, including their benefits, proper application methods, and expected outcomes.

The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.

Researchers found significant clinical benefits and tolerability with dual therapy for patients unresponsive to dupilumab alone.

A panelist discusses how precision medicine enables targeted atopic dermatitis treatments by matching specific therapies to patients based on their unique disease characteristics and biomarkers

A panelist discusses how initiating topical JAK inhibitors requires thorough patient education about proper application techniques, safety monitoring, and setting realistic expectations for treatment response timelines.

A panelist discusses how supporting patients with atopic dermatitis requires addressing both physical comorbidities and psychological health challenges simultaneously for optimal treatment outcomes.

As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in atopic dermatitis this year.

James Song, MD, FAAD, discusses how improving patient adherence to atopic dermatitis treatments requires addressing barriers such as cost, treatment complexity, and patient education, while highlighting how emerging therapies and simplified regimens may help overcome these challenges in the future.

A panelist discusses how the current treatment options for atopic dermatitis range from topical corticosteroids and calcineurin inhibitors for mild cases to systemic medications such as dupilumab and Janus kinase inhibitors for moderate-to-severe disease, with selection based on factors such as disease severity, patient age, and safety considerations.

James Song, MD, FAAD, discusses how recent advancements in atopic dermatitis treatment include targeted biologics and Janus kinase inhibitors that offer promising alternatives to traditional therapies for patients with moderate-to-severe disease.

A panelist discusses how the choice between systemic and topical treatments for pediatric atopic dermatitis (AD) depends on factors such as disease severity, impact on quality of life, affected body surface area, and response to previous therapies.

A panelist discusses how atopic dermatitis presents and is managed differently in adults vs children, with adults typically experiencing more localized lesions and chronic lichenification while children tend to have more widespread involvement and acute inflammation.

In a meta-analysis of over 61 million participants, it was found that AD patients have a 37% risk of developing IBD and similar conditions.

Karan Lal, DO, MS, FAAD, discusses how building a collaborative care network between parents, caregivers, and school staff is crucial for successful management of pediatric atopic dermatitis through consistent treatment application, trigger avoidance, and emergency response planning.

A panelist discusses how treating pediatric atopic dermatitis requires special attention to age-appropriate therapies, family education, adherence challenges, and the impact on children’s quality of life, including sleep and social development.

Karan Lal, DO, MS, FAAD, discusses how physicians can distinguish pediatric atopic dermatitis from similar skin conditions through key clinical features such as characteristic rash distribution, intense itching, and family history of atopic diseases.

Nemolizumab is intended for use in combination with topical corticosteroids and/or calcineurin inhibitors in this indication.

The approval is based on positive data stemming from the ADORING clinical trial program.

The supplemental New Drug Application is supported by positive results from the INTEGUMENT-PED and INTEGUMENT-OLE trials.

Join Dermatology Times’ quarterly editor in chief Raj Chovatiya, MD, PhD, MSCI, as he reviews key updates in atopic dermatitis.

Swanson and Lockshin explored how PDE4 inhibitors improve quality of life for AD patients through targeted treatments that address both inflammation and chronic symptoms.

The review found AD can disrupt family life, as caregiving responsibilities can lead to stress, guilt, and reduced opportunities for shared activities.

Panelists discuss how managing atopic dermatitis presents complex clinical challenges, including treatment resistance, medication adherence, identifying triggers, and tailoring therapies to individual patient needs and disease severity.

Panelists discuss how patients with atopic dermatitis face numerous obstacles to optimal care, including limited access to specialists, high treatment costs, inadequate insurance coverage, and the need for more effective long-term management options.

Panelists discuss how atopic dermatitis presents and requires different management approaches across age groups, with distinct challenges in diagnosis, treatment adherence, and quality of life impacts between pediatric and adult populations.